Synopsis
Synopsis
0
CEP/COS
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. (1,1'-biphenyl)-3-carboxylic Acid, 3'-((2z)-(1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene)hydrazino)-2'-hydroxy-
2. Ddl-701
3. Eltrombopag
4. Promacta
5. Revolade
6. Sb-497 115
7. Sb-497-115
8. Sb497115
1. 496775-62-3
2. Revolade
3. Promacta
4. Eltrombopag (olamine)
5. Unii-4u07f515lg
6. Sb-497115-gr
7. Eltrombopag Diethanolamine Salt
8. 496775-62-3 (olamine)
9. Eltrombopag (as Olamine)
10. 4u07f515lg
11. Sb-497115gr
12. Eltrombopag Compd With 2-aminoethanol (1:2)
13. Eltrombopag Diethanolamine Salt;sb-497115gr
14. (z)-3'-(2-(1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydro-4h-pyrazol-4-ylidene)hydrazinyl)-2'-hydroxy-[1,1'-biphenyl]-3-carboxyiic Acid;2-aminoethan-1-ol (1:2)
15. 3'-((2z)-2-(1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydro-4h-pyrazol-4-ylidene)diazanyl)-2'-hydroxybiphenyl-3-carboxylic Acid Compound With 2-aminoethanol (1:2)
16. Promacta Olamine
17. Eltrombopagolamine
18. Eltrombopag Olamine [usan:jan]
19. Promacta (tn)
20. Sb 497115gr
21. Schembl210183
22. Amy267
23. Chembl3989691
24. Schembl16207741
25. Schembl23458316
26. Eltrombopag Olamine (jan/usan)
27. Eltrombopag Olamine [jan]
28. Eltrombopag Olamine [usan]
29. Bcp07055
30. Eltrombopag Olamine [mart.]
31. Eltrombopag Olamine [who-dd]
32. Hy-15306a
33. Mfcd22380664
34. S2229
35. Akos025396658
36. Akos037515856
37. Ccg-270074
38. Cs-1566
39. Sb19102
40. Eltrombopag Olamine [orange Book]
41. 2-aminoethan-1-ol Hemi((e)-3'-(2-(2-(3,4-dimethylphenyl)-5-methyl-3-oxo-2,3-dihydro-1h-pyrazol-4-yl)hydrazono)-2'-oxo-2',3'-dihydro-[1,1'-biphenyl]-3-carboxylate)
42. Ac-26286
43. Bs-17370
44. Ft-0773802
45. D03978
46. A904098
47. Q27260489
48. Eltrombopag Compd With 2-aminoethanol (1:2) [mi]
49. (1,1'-biphenyl)-3-carboxylic Acid, 3'-((2z)-(1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene)hydrazino)-2'-hydroxy, Compound With 2-aminoethanol (1:2)
50. (1,1'-biphenyl)-3-carboxylic Acid, 3'-((2z)-(1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene)hydrazino)-2'-hydroxy-, Compound With 2-aminoethanol (1:2)
51. (1,1'-biphenyl)-3-carboxylic Acid, 3'-(2-(1-(3,4-dimethylphenyl)-4,5-dihydro-3-methyl-5-oxo-1h-pyrazol-4-yl)diazenyl)-2'-hydroxy-, Compd. With 2-aminoethanol (1:2)
52. 2-aminoethan-1-ol Hemi((z)-3'-(2-(1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydro-4h-pyrazol-4-ylidene)hydrazinyl)-2'-hydroxy-[1,1'-biphenyl]-3-carboxylate)
53. 2-aminoethanol (e)-3'-(2-(1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1h-pyrazol-4(5h)-ylidene)hydrazinyl)-2'-hydroxy-[1,1'-biphenyl]-3-carboxylate
54. 2-aminoethanol;3-[3-[[2-(3,4-dimethylphenyl)-5-methyl-3-oxo-1h-pyrazol-4-yl]diazenyl]-2-hydroxyphenyl]benzoic Acid
55. 3'-[(2z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic Acid Bis-(monoethanolamine)
56. 3'-[(2z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic Acid Bis-(monoethanolamine)
57. 3'-{(2z)-2-[1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydro-4h-pyrazol-4-ylidene]hydrazino}-2'-hydroxy-3-biphenylcarboxylic Acid 2-aminoethanol (1:2)
Molecular Weight | 564.6 g/mol |
---|---|
Molecular Formula | C29H36N6O6 |
Hydrogen Bond Donor Count | 7 |
Hydrogen Bond Acceptor Count | 11 |
Rotatable Bond Count | 7 |
Exact Mass | 564.26963289 g/mol |
Monoisotopic Mass | 564.26963289 g/mol |
Topological Polar Surface Area | 207 Ų |
Heavy Atom Count | 41 |
Formal Charge | 0 |
Complexity | 822 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 3 |
Revolade is indicated for the treatment of adult patients with primary immune thrombocytopenia (ITP) who are refractory to other treatments (e. g. corticosteroids, immunoglobulins) (see sections 4. 2 and 5. 1).
Revolade is indicated for the treatment of paediatric patients aged 1 year and above with primary immune thrombocytopenia (ITP) lasting 6 months or longer from diagnosis and who are refractory to other treatments (e. g. corticosteroids, immunoglobulins) (see sections 4. 2 and 5. 1).
Revolade is indicated in adult patients with chronic hepatitis C virus (HCV) infection for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy (see sections 4. 4 and 5. 1).
Revolade is indicated in adult patients with acquired severe aplastic anaemia (SAA) who were either refractory to prior immunosuppressive therapy or heavily pretreated and are unsuitable for haematopoietic stem cell transplantation (see section 5. 1).
B02BX05
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
Patent Expiration Date : 2038-11-05
US Patent Number : 11072586
Drug Substance Claim : Y
Drug Product Claim : Y
Application Number : 216774
Patent Use Code : U-3938
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2038-11-05
Patent Expiration Date : 2028-02-01
US Patent Number : 8052993*PED
Drug Substance Claim :
Drug Product Claim :
Application Number : 22291
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2028-02-01
Patent Expiration Date : 2027-08-01
US Patent Number : 8052994
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 22291
Patent Use Code : U-1714
Delist Requested :
Patent Use Description : TREATMENT OF THROMBOCY...
Patent Expiration Date : 2027-08-01
Patent Expiration Date : 2028-02-01
US Patent Number : 8828430*PED
Drug Substance Claim :
Drug Product Claim :
Application Number : 22291
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2028-02-01
Patent Expiration Date : 2025-07-13
US Patent Number : 7547719
Drug Substance Claim : Y
Drug Product Claim : Y
Application Number : 207027
Patent Use Code : U-1575
Delist Requested :
Patent Use Description : PATIENTS WITH SEVERE A...
Patent Expiration Date : 2025-07-13
Patent Expiration Date : 2027-08-01
US Patent Number : 8062665
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 22291
Patent Use Code : U-1306
Delist Requested :
Patent Use Description : TREATMENT OF THROMBOCY...
Patent Expiration Date : 2027-08-01
Patent Expiration Date : 2028-02-01
US Patent Number : 8052994*PED
Drug Substance Claim :
Drug Product Claim :
Application Number : 22291
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2028-02-01
Patent Expiration Date : 2027-08-01
US Patent Number : 8062665
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 22291
Patent Use Code : U-1714
Delist Requested :
Patent Use Description : TREATMENT OF THROMBOCY...
Patent Expiration Date : 2027-08-01
Patent Expiration Date : 2028-02-01
US Patent Number : 8828430*PED
Drug Substance Claim :
Drug Product Claim :
Application Number : 22291
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2028-02-01
Patent Expiration Date : 2025-07-13
US Patent Number : 7547719
Drug Substance Claim : Y
Drug Product Claim : Y
Application Number : 207027
Patent Use Code : U-1306
Delist Requested :
Patent Use Description : TREATMENT OF THROMBOCY...
Patent Expiration Date : 2025-07-13
ABOUT THIS PAGE
33
PharmaCompass offers a list of Eltrombopag API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Eltrombopag manufacturer or Eltrombopag supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Eltrombopag manufacturer or Eltrombopag supplier.
PharmaCompass also assists you with knowing the Eltrombopag API Price utilized in the formulation of products. Eltrombopag API Price is not always fixed or binding as the Eltrombopag Price is obtained through a variety of data sources. The Eltrombopag Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Revolade manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Revolade, including repackagers and relabelers. The FDA regulates Revolade manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Revolade API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Revolade manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Revolade supplier is an individual or a company that provides Revolade active pharmaceutical ingredient (API) or Revolade finished formulations upon request. The Revolade suppliers may include Revolade API manufacturers, exporters, distributors and traders.
click here to find a list of Revolade suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Revolade DMF (Drug Master File) is a document detailing the whole manufacturing process of Revolade active pharmaceutical ingredient (API) in detail. Different forms of Revolade DMFs exist exist since differing nations have different regulations, such as Revolade USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Revolade DMF submitted to regulatory agencies in the US is known as a USDMF. Revolade USDMF includes data on Revolade's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Revolade USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Revolade suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Revolade Drug Master File in Japan (Revolade JDMF) empowers Revolade API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Revolade JDMF during the approval evaluation for pharmaceutical products. At the time of Revolade JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Revolade suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Revolade Drug Master File in Korea (Revolade KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Revolade. The MFDS reviews the Revolade KDMF as part of the drug registration process and uses the information provided in the Revolade KDMF to evaluate the safety and efficacy of the drug.
After submitting a Revolade KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Revolade API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Revolade suppliers with KDMF on PharmaCompass.
A Revolade written confirmation (Revolade WC) is an official document issued by a regulatory agency to a Revolade manufacturer, verifying that the manufacturing facility of a Revolade active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Revolade APIs or Revolade finished pharmaceutical products to another nation, regulatory agencies frequently require a Revolade WC (written confirmation) as part of the regulatory process.
click here to find a list of Revolade suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Revolade as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Revolade API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Revolade as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Revolade and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Revolade NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Revolade suppliers with NDC on PharmaCompass.
Revolade Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Revolade GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Revolade GMP manufacturer or Revolade GMP API supplier for your needs.
A Revolade CoA (Certificate of Analysis) is a formal document that attests to Revolade's compliance with Revolade specifications and serves as a tool for batch-level quality control.
Revolade CoA mostly includes findings from lab analyses of a specific batch. For each Revolade CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Revolade may be tested according to a variety of international standards, such as European Pharmacopoeia (Revolade EP), Revolade JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Revolade USP).